@article{62dd6ea27ea540a2b0b96845a84ce77d,
title = "Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017)",
abstract = "Preclinical modeling and gene expression analyses have yielded distinct observations for the role of immune checkpoint, IDO1, in glioblastoma (GBM). Accordingly, our recent work differs with Garg et al. (2017) with respect to IDO1 among preclinical and bioinformatic GBM datasets. Here, we discuss the methodological differences that affected study interpretation, and potentially, future clinical decision-making for IDO1-targeting approaches against GBM.",
keywords = "IDO, Treg, brain tumor, glioblastoma, immunosuppression, immunotherapy",
author = "Lijie Zhai and Erik Ladomersky and Lauing, {Kristen L.} and Meijing Wu and Scholtens, {Denise M.} and Rohan Savoor and Bin Zhang and Wu, {Jennifer D.} and Craig Horbinski and Lukas, {Rimas V.} and Binder, {David C.} and Wainwright, {Derek A.}",
note = "Funding Information: This work was supported by NIH grants R00 NS082381 (D.A.W.); R01 NS097851-01 (D.A.W.); National Cancer Institute P50 CA221747 Project 2 (D.A.W. and R.V.L.), and T32 CA0070085 (E.L.). Publisher Copyright: {\textcopyright} 2018, {\textcopyright} 2018 Taylor & Francis Group, LLC.",
year = "2019",
month = mar,
day = "4",
doi = "10.1080/2162402X.2018.1548242",
language = "English (US)",
volume = "8",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "3",
}